Top

Published in:

01-06-2016 | Original Article

The effects of bufadienolides on HER2 overexpressing breast cancer cells

Authors: Tianjiao Wang, Lin Mu, Haifeng Jin, Peng Zhang, Yueyue Wang, Xiaochi Ma, Jinjin Pan, Jian Miao, Yuhui Yuan

Published in: Tumor Biology | Issue 6/2016

Abstract

HER2 is a proto-oncogene frequently amplified in human breast cancer, its overexpression is correlated with tamoxifen resistance and decreased recurrence-free survival. Arenobufagin and bufalin are homogeneous bufadienolides of cardiac glycosides agents. In this research, we studied the effects of arenobufagin and bufalin on cellular survival and proliferation of HER2 overexpressing breast cancer cells and the mechanism under the results including the direct effect on HER2 downstream pathways. Our results showed that arenobufagin and bufalin could significantly inhibit the proliferation and survival of HER2 overexpressing breast cancer cells, along with the declination of SRC-1, SRC-3, nuclear transcription factor E2F1, phosphorylated AKT, and ERK. And the combination of each bufadienolide in low dose with tamoxifen could significantly enhance the inhibitory effect of tamoxifen on HER2 overexpressing breast cancer cells. All above suggest that arenobufagin and bufalin may be potential therapy adjuvants for HER2 overexpressing breast cancer therapy.

Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.CrossRefPubMed

Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003;95:353–61.CrossRefPubMed

Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004;96:926–35.CrossRefPubMed

Yin L, Zhang XT, Bian XW, Guo YM, Wang ZY. Disruption of the ER-alpha36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells. PLoS One. 2014;9, e107369.CrossRefPubMedPubMedCentral

Moon YW, Park S, Sohn JH, Kang DR, Koo JS, Park HS, et al. Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. J Cancer Res Clin Oncol. 2011;137:1123–30.CrossRefPubMed

Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366:2–16.CrossRefPubMed

Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999–2004. Breast J. 2009;15:593–602.CrossRefPubMed

Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1992;24:85–95.CrossRefPubMed

Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–12.CrossRefPubMed

10.

Hubalek M, Brunner C, Mattha K, Marth C. Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment. Wien Med Wochenschr. 2010;160:506–12.CrossRefPubMed

11.

Ross JS. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy. Drug News Perspect. 2009;22:93–106.CrossRefPubMed

12.

Liang Y, Liu AH, Qin S, Sun JH, Yang M, Li P, et al. Simultaneous determination and pharmacokinetics of five bufadienolides in rat plasma after oral administration of Chansu extract by SPE-HPLC method. J Pharm Biomed Anal. 2008;46:442–8.CrossRefPubMed

13.

Wang Y, Lonard DM, Yu Y, Chow DC, Palzkill TG, Wang J, et al. Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. Cancer Res. 2014;74:1506–17.CrossRefPubMedPubMedCentral

14.

Cruz Jdos S, Matsuda H. Arenobufagin, a compound in toad venom, blocks Na(+)-K+ pump current in cardiac myocytes. Eur J Pharmacol. 1993;239:223–6.CrossRefPubMed

15.

Cruz Jdos S, Matsuda H. Depressive effects of arenobufagin on the delayed rectifier K+ current of guinea-pig cardiac myocytes. Eur J Pharmacol. 1994;266:317–25.CrossRefPubMed

16.

Zhang DM, Liu JS, Deng LJ, Chen MF, Yiu A, Cao HH, et al. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Carcinogenesis. 2013;34:1331–42.CrossRefPubMed

17.

Li M, Wu S, Liu Z, Zhang W, Xu J, Wang Y, et al. Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway. Biochem Pharmacol. 2012;83:1251–60.CrossRefPubMed

18.

Yin P-H, Liu X, Qiu Y-Y, Cai J-F, Qin J-M, Zhu H-R, et al. Anti-tumor activity and apoptosis-regulation mechanisms of bufalin in various cancers: new hope for cancer patients. Asian Pac J Cancer Prev. 2012;13:5339–43.CrossRefPubMed

19.

Yuan Y, Qin L, Liu D, Wu RC, Mussi P, Zhou S, et al. Genetic screening reveals an essential role of p27kip1 in restriction of breast cancer progression. Cancer Res. 2007;67:8032–42.CrossRefPubMedPubMedCentral

20.

Li J, Ma X, Li F, Wang J, Chen H, Wang G, et al. Preparative separation and purification of bufadienolides from Chinese traditional medicine of Chansu using high-speed counter-current chromatography. J Sep Sci. 2010;33:1325–30.PubMed

21.

Wright C, Nicholson S, Angus B, Sainsbury JR, Farndon J, Cairns J, et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer. 1992;65:118–21.CrossRefPubMedPubMedCentral

22.

Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney Jr DW, et al. Structure of the extracellular region of HER2 alone and in complex with the herceptin fab. Nature. 2003;421:756–60.CrossRefPubMed

23.

Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT, et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for Gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2005;11:3750–7.CrossRef

24.

Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res. 2003;284:54–65.CrossRefPubMed

25.

Ben-Levy R, Paterson HF, Marshall CJ, Yarden Y. A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the map kinase pathway. EMBO J. 1994;13:3302–11.PubMedPubMedCentral

26.

Prigent SA, Gullick WJ. Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J. 1994;13:2831–41.PubMedPubMedCentral

27.

Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441:424–30.CrossRefPubMed

28.

Kirkegaard T, McGlynn LM, Campbell FM, Muller S, Tovey SM, Dunne B, et al. Amplified in breast cancer 1 in human epidermal growth factor receptor—positive tumors of tamoxifen-treated breast cancer patients. Clin Cancer Res: Off J Am Assoc Cancer Res. 2007;13:1405–11.CrossRef

29.

Bouras T, Southey MC, Venter DJ. Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Cancer Res. 2001;61:903–7.PubMed

30.

Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science. 1997;277:965–8.CrossRefPubMed

31.

Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 2000;14:121–41.PubMed

32.

Takeshita A, Cardona GR, Koibuchi N, Suen CS, Chin WW. TRAM-1, a novel 160-kDa thyroid hormone receptor activator molecule, exhibits distinct properties from steroid receptor coactivator-1. J Biol Chem. 1997;272:27629–34.CrossRefPubMed

33.

Louie MC, Zou JX, Rabinovich A, Chen HW. ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol Cell Biol. 2004;24:5157–71.CrossRefPubMedPubMedCentral

34.

Wu RC, Qin J, Hashimoto Y, Wong J, Xu J, Tsai SY, et al. Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) coactivator activity by I kappa B kinase. Mol Cell Biol. 2002;22:3549–61.CrossRefPubMedPubMedCentral

35.

Yan J, Yu CT, Ozen M, Ittmann M, Tsai SY, Tsai MJ. Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. Cancer Res. 2006;66:11039–46.CrossRefPubMed

36.

Xu J, Liao L, Ning G, Yoshida-Komiya H, Deng C, O’Malley BW. The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc Natl Acad Sci U S A. 2000;97:6379–84.CrossRefPubMedPubMedCentral

37.

Wang Z, Rose DW, Hermanson O, Liu F, Herman T, Wu W, et al. Regulation of somatic growth by the p160 coactivator p/CIP. Proc Natl Acad Sci U S A. 2000;97:13549–54.CrossRefPubMedPubMedCentral

38.

Qin L, Wu YL, Toneff MJ, Li D, Liao L, Gao X, et al. NCOA1 directly targets M-CSF1 expression to promote breast cancer metastasis. Cancer Res. 2014;74:3477–88.CrossRefPubMedPubMedCentral

39.

Walsh CA, Bolger JC, Byrne C, Cocchiglia S, Hao Y, Fagan A, et al. Global gene repression by the steroid receptor coactivator SRC-1 promotes oncogenesis. Cancer Res. 2014;74:2533–44.CrossRefPubMed

40.

Bracken AP, Ciro M, Cocito A, Helin K. E2F target genes: unraveling the biology. Trends Biochem Sci. 2004;29:409–17.CrossRefPubMed

41.

DeGregori J, Johnson DG. Distinct and overlapping roles for E2F family members in transcription, proliferation and apoptosis. Curr Mol Med. 2006;6:739–48.PubMed

42.

Sharma N, Timmers C, Trikha P, Saavedra HI, Obery A, Leone G. Control of the p53-p21cip1 axis by E2f1, E2f2, and E2f3 is essential for G1/S progression and cellular transformation. J Biol Chem. 2006;281:36124–31.CrossRefPubMed

43.

Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet. 2001;10:699–703.CrossRefPubMed

44.

Andrechek ER. HER2/neu tumorigenesis and metastasis is regulated by e2f activator transcription factors. Oncogene. 2013.

45.

Lahusen T, Fereshteh M, Oh A, Wellstein A, Riegel AT. Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1. Cancer Res. 2007;67:7256–65.CrossRefPubMedPubMedCentral

46.

Razandi M, Pedram A, Park ST, Levin ER. Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem. 2003;278:2701–12.CrossRefPubMed

47.

Font de Mora J, Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol. 2000;20:5041–7.CrossRef

48.

Nass N, Kalinski T. Tamoxifen resistance: from cell culture experiments towards novel biomarkers. Pathol Res Pract. 2015;211:189–97.CrossRefPubMed

49.

Burandt E, Jens G, Holst F, Janicke F, Muller V, Quaas A, et al. Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer. Breast Cancer Res Treat. 2013;137:745–53.CrossRefPubMed

Title: The effects of bufadienolides on HER2 overexpressing breast cancer cells
Authors: Tianjiao Wang
Lin Mu
Haifeng Jin
Peng Zhang
Yueyue Wang
Xiaochi Ma
Jinjin Pan
Jian Miao
Yuhui Yuan
Publication date: 01-06-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 6/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4381-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2016

Garcinol inhibits tumour cell proliferation, angiogenesis, cell cycle progression and induces apoptosis via NF-κB inhibition in oral cancer

MiR-205 functions as a tumor suppressor in adenocarcinoma and an oncogene in squamous cell carcinoma of esophagus

Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine

Downregulation of SATB1 increases the invasiveness of Jurkat cell via activation of the WNT/β-catenin signaling pathway in vitro

RETRACTED ARTICLE: Evaluation of gene expression level of CDC5L and MACC1 in poor prognosis and progression of osteosarcoma

RETRACTED ARTICLE: Upregulation of microRNA-31 targeting integrin α5 suppresses tumor cell invasion and metastasis by indirectly regulating PI3K/AKT pathway in human gastric cancer SGC7901 cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer